View Item 

Show simple item record

Human T‐cell lymphotrophic virus in solid‐organ transplant recipients: Guidelines from the American society of transplantation infectious diseases community of practice
dc.contributor.authorKaul, Daniel R.
dc.contributor.authorSharma, Tanvi S.
dc.date.accessioned2019-10-30T15:31:23Z
dc.date.availableWITHHELD_12_MONTHS
dc.date.available2019-10-30T15:31:23Z
dc.date.issued2019-09
dc.identifier.citationKaul, Daniel R.; Sharma, Tanvi S. (2019). "Human T‐cell lymphotrophic virus in solid‐organ transplant recipients: Guidelines from the American society of transplantation infectious diseases community of practice." Clinical Transplantation 33(9): n/a-n/a.
dc.identifier.issn0902-0063
dc.identifier.issn1399-0012
dc.identifier.urihttps://hdl.handle.net/2027.42/151899
dc.description.abstractThese updated guidelines from the Infectious Diseases Community of Practice of the American Society of Transplantation review the diagnosis, prevention, and management of Human T‐cell lymphotrophic virus 1 (HTLV)‐1 in the pre‐ and post‐transplant period. HTLV‐1 is an oncogenic human retrovirus rare in North America but endemic in the Caribbean and parts of Africa, South America, Asia, and Oceania. While most infected persons do not develop disease, <5% will develop adult T‐cell leukemia/lymphoma or neurological disease. No proven antiviral treatment for established HTLV‐1 infection is available. The effect of immunosuppression on the development of HTLV‐1‐associated disease in asymptomatically infected recipients is not well characterized, and HTLV‐1‐infected individuals should be counseled that immunosuppression may increase the risk of developing HTLV‐1‐associated disease and they should be monitored post‐transplant for HTLV‐1‐associated disease. Currently approved screening assays do not distinguish between HTLV‐1 and HTLV‐2, and routine screening of deceased donors without risk factors in low seroprevalence areas is likely to result in significant organ wastage and is not recommended. Targeted screening of donors with risk factors for HTLV‐1 infection and of living donors (as time is available to perform confirmatory tests) is reasonable.
dc.publisherWiley Periodicals, Inc.
dc.subject.otherinfection and infectious agents
dc.subject.otherviral: human T‐lymphotropic virus
dc.subject.otherdonors and donation: donor‐derived infections
dc.subject.othercomplication: infectious
dc.titleHuman T‐cell lymphotrophic virus in solid‐organ transplant recipients: Guidelines from the American society of transplantation infectious diseases community of practice
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMedicine (General)
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/151899/1/ctr13575.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/151899/2/ctr13575_am.pdf
dc.identifier.doi10.1111/ctr.13575
dc.identifier.sourceClinical Transplantation
dc.identifier.citedreferenceTreviño A, Parra P, Bar‐Magen T, Garrido C, de Mendoza C, Soriano V. Antiviral effect of raltegravir on HTLV‐1 carriers. J Antimicrob Chemother. 2012; 67 ( 1 ): 218 ‐ 221.
dc.identifier.citedreferenceTajima Y, Matsumura M, Yaguchi H, Mito Y. Two cases of human T‐lymphotropic virus Type I‐associated myelopathy/tropical spastic paraparesis caused by living‐donor renal transplantation. Case Rep Neurol Med. 2016; 2016: 4203079.
dc.identifier.citedreferenceYamauchi J, Yamano Y, Yuzawa K. Risk of human T‐cell Leukemia virus Type 1 infection in kidney transplantation. N Engl J Med. 2019; 380 ( 3 ): 296 ‐ 298.
dc.identifier.citedreferenceLee TH, Chafets DM, Busch MP, Murphy EL. Quantitation of HTLV‐I and II proviral load using real‐time quantitative PCR with SYBR green chemistry. J Clin Virol. 2004; 31 ( 4 ): 275 ‐ 282.
dc.identifier.citedreferencePackage insert: Abbott HTLV‐I/HTLV‐II EIA.
dc.identifier.citedreferenceGout O, Gessain A, Iba‐Zizen MT, et al. The effect of zidovudine on chronic myelopathy associated with HTLV‐1. J Neurol. 1991; 238 ( 2 ): 108 ‐ 109.
dc.identifier.citedreferenceMartin F, Taylor GP. Prospects for the management of human T‐cell lymphotropic virus type 1‐associated myelopathy. AIDS Rev. 2011; 13 ( 3 ): 161 ‐ 170.
dc.identifier.citedreferenceSheremata WA, Benedict D, Squilacote DC, Sazant A, DeFreitas E. High‐dose zidovudine induction in HTLV‐I‐associated myelopathy: safety and possible efficacy. Neurology. 1993; 43 ( 10 ): 2125 ‐ 2129.
dc.identifier.citedreferenceTaylor GP, Goon P, Furukawa Y, et al. Zidovudine plus lamivudine in Human T‐Lymphotropic Virus type‐I‐associated myelopathy: a randomised trial. Retrovirology. 2006; 3: 63.
dc.identifier.citedreferenceHuang RC, Fishman JA. Screening of deceased organ donors: no easy answers. Transplantation. 2011; 91 ( 2 ): 146 ‐ 149.
dc.identifier.citedreferenceFood and Drug Administration. 2012; www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/licensedProductsBLAs/BloodDonorScreening/InfectiousDisease/ucm090707.htm.
dc.identifier.citedreferenceGrassi M, Olavarria VN, Kruschewsky R, et al. T cell lymphotropic virus type 1 (HTLV‐1) proviral load of HTLV‐associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients according to new diagnostic criteria of HAM/TSP. J Med Virol. 2011; 83 ( 7 ): 1269 ‐ 1274.
dc.identifier.citedreferenceSilva MT, Harab RC, Leite AC, Schor D, Araujo A, Andrada‐Serpa MJ. Human T lymphotropic virus type 1 (HTLV‐1) proviral load in asymptomatic carriers, HTLV‐1‐associated myelopathy/tropical spastic paraparesis, and other neurological abnormalities associated with HTLV‐1 infection. Clin Infect Dis. 2007; 44 ( 5 ): 689 ‐ 692.
dc.identifier.citedreferenceGoncalves DU, Proietti FA, Ribas J, et al. Epidemiology, treatment, and prevention of human T‐cell leukemia virus type 1‐associated diseases. Clin Microbiol Rev. 2010; 23 ( 3 ): 577 ‐ 589.
dc.identifier.citedreferenceKataoka R, Takehara N, Iwahara Y, et al. Transmission of HTLV‐I by blood transfusion and its prevention by passive immunization in rabbits. Blood. 1990; 76 ( 8 ): 1657 ‐ 1661.
dc.identifier.citedreferenceMenna‐Barreto M. HTLV‐II transmission to a health care worker. Am J Infect Control. 2006; 34 ( 3 ): 158 ‐ 160.
dc.identifier.citedreferenceAmin RM, Jones B, Rubert M, et al. Risk of retroviral infection among retrovirology laboratory and health care workers. American society for Microbiology 92nd general meeting, New Orleans, Louisiana, May 26–30, 1992. {abstract T‐20}.
dc.identifier.citedreferenceElectronic Therapeutic Guidelines. http://www.tg.org.au/etg_demo/tgc/abg/4651.htm#4703ID_GL.
dc.identifier.citedreferenceSeegulam ME, Ratner L. Integrase inhibitors effective against human T‐cell leukemia virus type 1. Antimicrob Agents Chemother. 2011; 55 ( 5 ): 2011 ‐ 2017.
dc.identifier.citedreferenceHaynes R, Ware E, Premanandan C, et al. Cyclosporine‐induced immune suppression alters establishment of HTLV‐1 infection in a rabbit model. Blood. 2010; 115 ( 4 ): 815 ‐ 823.
dc.identifier.citedreferenceMahieux R, Gessain A. The human HTLV‐3 and HTLV‐4 retroviruses: new members of the HTLV family. Pathol Biol. 2009; 57 ( 2 ): 161 ‐ 166.
dc.identifier.citedreferenceTagaya Y, Gallo RC. The exceptional oncogenicity of HTLV‐1. Front Microbiol. 2017; 8: 1425.
dc.identifier.citedreferenceMurphy E, Roucoux D. The epidemiology and disease outcomes of human T‐lymphotropic virus type II. AIDS Rev. 2004; 6 ( 3 ): 144 ‐ 154.
dc.identifier.citedreferenceBlattner WA, Saxinger C, Riedel D, et al. A study of HTLV‐I and its associated risk factors in Trinidad and Tobago. J Acquir Immune Defic Syndr. 1990; 3 ( 11 ): 1102 ‐ 1108.
dc.identifier.citedreferenceProietti FA, Carneiro‐Proietti AB, Catalan‐Soares BC, Murphy EL. Global epidemiology of HTLV‐I infection and associated diseases. Oncogene. 2005; 24 ( 39 ): 6058 ‐ 6068.
dc.identifier.citedreferenceGlynn SA, Kleinman SH, Schreiber GB et al. Trends in incidence and prevalence of major transfusion‐transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS). JAMA. 2000; 284 ( 2 ): 229 ‐ 235.
dc.identifier.citedreferenceClaquin J, Romano P, Noury D, et al. Human T lymphotropic virus 1–2 positive antibodies in potential organ donors in France. Transpl Proc. 1996; 28 ( 1 ): 189 ‐ 190.
dc.identifier.citedreferenceKaul DR, Taranto S, Alexander C, et al. Donor screening for human T‐cell lymphotrophic virus 1/2: changing paradigms for changing testing capacity. Am J Transplant. 2010; 10 ( 2 ): 207 ‐ 213.
dc.identifier.citedreferenceTedla F, Brar A, John D, Sumrani N. Risk of transmission of human T‐lymphotropic virus through transplant. Am J Transplant. 2015; 15 ( 4 ): 1123 ‐ 1124.
dc.identifier.citedreferenceCarneiro‐Proietti AB, Amaranto‐Damasio MS, Leal‐Horiguchi CF, et al. Mother‐to‐child transmission of human T‐cell lymphotropic viruses‐1/2: what we know, and what are the gaps in understanding and preventing this route of infection. J Pediatric Infect Dis Soc. 2014; 3 ( Suppl 1 ): S24 ‐ 29.
dc.identifier.citedreferenceManns A, Wilks RJ, Murphy EL, et al. A prospective study of transmission by transfusion of HTLV‐I and risk factors associated with seroconversion. Int J Cancer. 1992; 51 ( 6 ): 886 ‐ 891.
dc.identifier.citedreferenceMartin‐Davila P, Fortun J, Lopez‐Velez R, et al. Transmission of tropical and geographically restricted infections during solid‐organ transplantation. Clin Microbiol Rev. 2008; 21 ( 1 ): 60 ‐ 96.
dc.identifier.citedreferenceAoki R, Karube K, Sugita Y, et al. Distribution of malignant lymphoma in Japan: analysis of 2260 cases, 2001–2006. Pathol Int. 2008; 58 ( 3 ): 174 ‐ 182.
dc.identifier.citedreferencede Oliveira Mde F, Fatal PL, Primo JR, et al. Infective dermatitis associated with human T‐cell lymphotropic virus type 1: evaluation of 42 cases observed in Bahia. Brazil. Clin Infect Dis. 2012; 54 ( 12 ): 1714 ‐ 1719.
dc.identifier.citedreferenceNakamura N, Tamaru S, Ohshima K, Tanaka M, Arakaki Y, Miyauchi T. Prognosis of HTLV‐I‐positive renal transplant recipients. Transpl Proc. 2005; 37 ( 4 ): 1779 ‐ 1782.
dc.identifier.citedreferenceTanabe K, Kitani R, Takahashi K, et al. Long‐term results in human T‐cell leukemia virus type 1‐positive renal transplant recipients. Transpl Proc. 1998; 30 ( 7 ): 3168 ‐ 3170.
dc.identifier.citedreferenceShirai H, Suzuki M, Tomita Y, et al. Renal transplantation in patients with human T‐cell lymphotropic virus type 1. Transplant Proc. 2012; 44 ( 1 ): 83 ‐ 86.
dc.identifier.citedreferenceHoshida Y, Li T, Dong Z, et al. Lymphoproliferative disorders in renal transplant patients in Japan. Int J Cancer. 2001; 91 ( 6 ): 869 ‐ 875.
dc.identifier.citedreferenceYoshizumi T, Shirabe K, Ikegami T, et al. Impact of human T cell leukemia virus type 1 in living donor liver transplantation. Am J Transplant. 2012; 12 ( 6 ): 1479 ‐ 1485.
dc.identifier.citedreferenceMarvin MR, Brock GN, Kwarteng K, et al. Increasing utilization of human T‐cell lymphotropic virus (+) donors in liver transplantation: is it safe? Transplantation. 2009; 87 ( 8 ): 1180 ‐ 1190.
dc.identifier.citedreferenceShames BD, D’Alessandro AM, Sollinger HW. Human T‐cell lymphotrophic virus infection in organ donors: a need to reassess policy? Am J Transplant. 2002; 2 ( 7 ): 658 ‐ 663.
dc.identifier.citedreferenceNakamura N, Arakaki Y, Sunagawa H, et al. Influence of immunosuppression in HTLV‐1‐positive renal transplant recipients. Transpl Proc. 1998; 30 ( 4 ): 1324 ‐ 1326.
dc.identifier.citedreferenceRemesar MC, del Pozo AE, Pittis MG, Mangano AM, Sen L, Briones L. Transmission of HTLV‐I by kidney transplant. Transfusion. 2000; 40 ( 11 ): 1421 ‐ 1422.
dc.identifier.citedreferenceYara S, Fujita J, Date H. Transmission of human T‐lymphotropic virus type I by bilateral living‐donor lobar lung transplantation. J Thorac Cardiovasc Surg. 2009; 138 ( 1 ): 255 ‐ 256.
dc.identifier.citedreferenceGövert F, Krumbholz A, Witt K, et al. HTLV‐1 associated myelopathy after renal transplantation. J Clin Virol. 2015; 72: 102 ‐ 105.
dc.identifier.citedreferenceMontesdeoca Andrade MJ, Correa Diaz EP, Buestan ME. HTLV‐1‐associated myelopathy in a solid organ transplant recipient. BMJ Case Rep. 2016; 2016: bcr2016215243.
dc.identifier.citedreferenceMoreno‐Ajona D, Yuste JR, Martin P, Gallego P‐L. HTLV‐1 myelopathy after renal transplant and antiviral prophylaxis: the need for screening. J Neurovirol. 2018; 24 ( 4 ): 523 – 525.
dc.identifier.citedreferenceNagamine Y, Hayashi T, Kato Y, Horiuchi Y, Tanahashi N. Human T lymphotropic virus type‐1‐associated myelopathy manifesting shortly after living‐donor renal transplantation. Intern Med. 2015; 54 ( 1 ): 75 ‐ 78.
dc.identifier.citedreferenceRamanan P, Deziel PJ, Norby SM, Yao JD, Garza I, Razonable RR. Donor‐transmitted HTLV‐1‐associated myelopathy in a kidney transplant recipient–case report and literature review. Am J Transplant. 2014; 14 ( 10 ): 2417 ‐ 2421.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ctr13575.pdf
Size:
604.9KB
Format:
PDF
View/Open
Name:
ctr13575_am.pdf
Size:
227.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.